https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/365 Fri, 03 Jul 2026 23:11:04 GMT 2026-07-03T23:11:04Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/214437 Title: Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria Authors: Won, Chong Hyun; Park, Chun Wook; Ahn, Jiyoung; Ko, Joo Yeon; Cho, Sang Hyun; Lee, Yang Won; Lee, Joo Hee; Ng, Khai Jing; Hong, Min Young; Zhong, Jinglin; Dossenbach, Martin; Son, Sang Wook Abstract: Background Lebrikizumab is approved to treat patients with moderate-to-severe atopic dermatitis (AD). Objectives This study evaluated the 16-week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement-like criteria. Methods This was a post-hoc analysis of pooled data from ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). Patients were randomised 2:1 to receive lebrikizumab or placebo every 2 weeks. Two non-mutually exclusive subgroups were selected based on South Korean reimbursement-like criteria: Eczema Area and Severity Index (EASI) score >= 23, AD duration >= 3 years, and previous use of any systemic treatment (ST subgroup) or previous treatment with cyclosporine or methotrexate (CM subgroup). Week-16 outcomes were Investigator's Global Assessment score of 0 or 1 (IGA [0,1]) with >= 2-point improvement, >= 50%/75%/90% improvement in EASI score (EASI 50/75/90), Pruritus Numeric Rating Scale (NRS) >= 4-point improvement, and Dermatology Life Quality Index (DLQI) >= 4-point improvement. Response rates to lebrikizumab and placebo were analysed using Cochran-Mantel-Haenszel tests. Common risk differences and 95% confidence intervals were reported. Results The ST subgroup included 322 patients, and the CM subgroup included 111 patients. More lebrikizumab-treated than placebo-treated patients achieved outcome responses. Percentage differences in favour of lebrikizumab (p < 0.01) were: IGA (0,1): ST = 25.7% (18.2%-33.1%), CM = 20.8% (7.9%-33.7%); EASI 50: ST = 42.7% (32.5%-52.9%), CM = 36.9% (19.8%-54.0%); EASI 75: ST = 40.2% (31.4%-49.1%), CM = 33.3% (19.1%-47.5%); EASI 90: ST = 27.4% (20.3%-34.5%), CM = 22.1% (11.3%-32.8%); Pruritus NRS >= 4-point improvement: ST = 34.7% (26.7%-42.7%), CM = 26.7% (14.9%-38.4%); and DLQI >= 4-point improvement: ST = 44.2% (33.2%-55.2%), CM = 39.5% (20.2%-58.8%). Conclusions In this post-hoc, exploratory subgroup analysis, lebrikizumab improved AD skin and pruritus at week 16 in adults and adolescents who would be eligible for treatment based on South Korean reimbursement-like criteria. Mon, 01 Jun 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/214437 2026-06-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/217707 Title: Evaluation of carbon-dioxide laser grinding as a treatment for ingrown toenail Authors: Kim, Sun Gyu; Ahn, Woo Jin; Seo, Hyun-Min; Kim, Joung Soo Abstract: [No abstract available] Fri, 01 May 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/217707 2026-05-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/213942 Title: PRMT1 Inhibition Targets BNC1-Dependent Proliferation in Squamous Cell Carcinoma Authors: Boudra, Rafik; Patenall, Bethany L.; King, Sandra L.; Carter, Kristyn A.; Wang, Diana; Best, Sarah A.; Ko, Joo Yeon; Xu, Shuyun; Fang, Rui; Padilla, Maria G.; Schmults, Chrysalyne D.; Barthel, Steven R.; Lian, Christine G.; Ramsey, Matthew R. Abstract: Transcription factor complexes integrate diverse signals into discrete physiological outputs and are often aberrantly regulated in malignancies such as squamous cell carcinoma (SCC). In this study, we sought to discover new transcriptional complexes essential for SCC tumor maintenance, which have catalytic activities that can be targeted to provide new therapeutic options for patients with SCC. Comparing expression patterns of SCC tumors with those of non-SCC tumors, we have identified basonuclin 1 as a highly expressed, SCC-specific transcription factor. Analysis of direct transcriptional targets has uncovered an essential role for basonuclin 1 in controlling the proliferation–differentiation–migration axis. Basonuclin 1 activates proliferation genes while repressing a FRA1-dependent promigratory program and IRF6-dependent differentiation program. In addition, basonuclin 1 physically interacts with PRMT1 (protein arginine methyltransferase 1) to activate cell cycle genes. Importantly, proliferation can be blocked in SCC tumors using PRMT1 inhibitors, which has no effect on the repression of promigratory genes. Given the diverse gene expression programs regulated by transcription factors, this work demonstrates that protumorigenic activities can be specifically targeted through the inhibition of cofactors without activating pathways that may lead to tumor progression. Wed, 01 Apr 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/213942 2026-04-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/211559 Title: Energy-Based Devices for the Treatment of Cutaneous Lesions in Patients With Lupus Erythematosus and Dermatomyositis Authors: Joh, Hae chang; Jue, Mihn-Sook; Ko, Joo Yeon Abstract: Background: The use of energy-based devices (EBDs) for aesthetic and dermatological conditions is increasing, but data on efficacy and safety in autoimmune connective tissue disease (CTD) patients remain limited. Objectives: This study assesses EBD real-world treatment outcomes in Korean patients with lupus erythematosus (LE) and dermatomyositis (DM). Methods: A retrospective, uncontrolled study was conducted on 26 CTD patients (LE: 20, DM: 6) treated at Hanyang University Seoul Hospital (2015–2023). Various laser modalities, including pulsed-dye laser (PDL), intense pulsed light (IPL), long-pulse Nd:YAG (LPNY), Q-switched Nd:YAG (QSNY), and ablative fractional laser (AFL), were analyzed. Two independent dermatologists evaluated treatment outcomes using a 5-point modified Investigator's Global Assessment (IGA) scale. Results: Patients showed significant improvement in erythema, dyspigmentation, and overall skin morphology. Some LE patients also exhibited enhanced follicular activity. Treatments were well-tolerated, with only transient side effects reported, and no long-term complications or disease reactivation occurred. Conclusions: EBD treatments may provide cosmetic improvement in selected LE and DM patients and are generally safe. Larger controlled studies are needed to confirm efficacy and establish optimal protocols. Thu, 01 Jan 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/211559 2026-01-01T00:00:00Z